ReviewCancer genomics & proteomics
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Review in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.Annals of hematology · 2024Pooled it
- Successful treatment of relapsedTherapeutic advances in hematology · 2026Article
- Prognostic value of an eighteen-genes panel in acute myeloid leukemia by analyzing TARGET and TCGA databases.Cancer biomarkers : section A of Disease markers · 2023Article
- Article
- High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML).Cancer reports (Hoboken, N.J.) · 2022Article
- Identification ofJournal of oncology · 2021Article
- The Clinicopathological Impact of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression and Different Molecular Prognostic Biomarkers in Egyptian Acute Myeloid Leukemia Patients.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.Current treatment options in oncology · 2020Review
- CircRAD18 Accelerates the Progression of Acute Myeloid Leukemia by Modulation of miR-206/PRKACB Axis.Cancer management and research · 2020Article
- Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p/AKT3 axis.Cancer cell international · 2020Article
- Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.Journal of oncology · 2019Review
- microRNA-628 inhibits the proliferation of acute myeloid leukemia cells by directly targeting IGF-1R.OncoTargets and therapy · 2019Article
- PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway.OncoTargets and therapy · 2019Article
- Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.Oncology letters · 2018Article
- Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.Scientific reports · 2018Article
- Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.Journal of neuro-oncology · 2017Article
- MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.Oncotarget · 2017Article
- PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.Journal of translational medicine · 2017Article
- The biomarkers of leukemia stem cells in acute myeloid leukemia.Stem cell investigation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence increases with age. Cytogenetics and mutation testing remain important prognostic tools for treatment after induction therapy. The post-induction treatment is dependent on risk stratification. Despite rapid advances in determination of gene mutations involved in the pathophysiology and biology of AML, and the rapid development of new drugs, treatment improvements changed slowly over the past 30 years, with the majority of patients eventually experiencing relapse and dying of their disease. Allogenic hematopoietic stem cell transplantation remains the best chance of cure for patients with intermediate- or high-risk disease. This review gives an overview about advances in prognostic markers and novel treatment options for AML, focusing on new prognostic and probably therapeutic mutations, and novel drug therapies such as tyrosine kinase inhibitors.
Indexed as
Identifiers
27566651PMC5070622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.